WO1998033932A1 - Lipid emulsions as gene transfection agents and method of preparing said emulsions - Google Patents
Lipid emulsions as gene transfection agents and method of preparing said emulsions Download PDFInfo
- Publication number
- WO1998033932A1 WO1998033932A1 PCT/KR1998/000020 KR9800020W WO9833932A1 WO 1998033932 A1 WO1998033932 A1 WO 1998033932A1 KR 9800020 W KR9800020 W KR 9800020W WO 9833932 A1 WO9833932 A1 WO 9833932A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- dna
- emulsion
- emulsions
- brc
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
Definitions
- the present invention relates to oil-in-water lipid emulsions used as gene transfection agents and method for preparing the emulsions.
- the present invention also concerns the method of transferring genes efficiently into cells by using the lipid emulsions.
- the lipid emulsion of the present invention comprises a combination of 2 to 30 (w/w)% of one or more oils selected from vegetable oils and/or triacylglycerols having 8 to 12 carbons in hydrocarbon chains, 0.01 to 20 (w/w)% of one or more emulsifiers including cationic biological surface-active agent, and an aqueous solution, in addition, other additives may be optionally added.
- the emulsions of the present invention can transfer genes into the cytoplasm. These emulsions are very stable, and can transfer genes into the cells in the presence of serum. Therefore, the emulsions of the present invention can be used in clinical gene therapy.
- cationic liposomal reagents are commercially available and are widely used for gene transfection since they are able to interact strongly with both negatively charged genetic materials and plasma membranes. They have been proven to be highly effective reagents for the transfection of DNA, RNA, and oligonucleotides in a wide variety of cell lines. Unlike other available transfection agents, cationic liposomes are safe and have low cytotoxicity. They are also relatively efficient for in vitro applications. Most cationic liposomes, however, form aggregates with a high concentration of DNA, and its transfection efficiency decreases sharply in the presence of serum. These factors hamper the in vivo application of gene transfer.
- An emulsion is a stable dispersion of one liquid in a second immiscible liquid, and typically, a surface-active agent is used to maintain its stability.
- Emulsions made of an oil dispersed in an aqueous phase with a suitable emulsifying agent have an important part in drug delivery, as well as for delivery of parenteral nutrition.
- the lipid emulsions also known as a fat emulsion or a lipid microsphere
- soybean oil and stabilized by phospholipids have been used successfully as a carrier of iipophilic drugs, since they mimic the chylomicron which is a natural fat particle that presents in the blood.
- a lipid emulsion could be formulated to be very stable and can be stored at room temperature for two years. For instance, parenteral emulsions have no known side-effects, even at dosage levels of 500 ml.
- Lipid emulsions are known to distribute in various tissues similar to liposomes. Therefore, the lipid emulsion can replace liposomes in many applications. It has also been reported that lipid emulsions are more stable than liposomes in the blood circulation.
- the present invention relates to an oil-in-water (o/w) type lipid 5 emulsions and method of preparing the emulsions that can deliver genes and biologically active materials into cells.
- the lipid emulsion of the present invention comprises a combination of 2 to 30 (w/w)% of one or more oils selected from vegetable oils and/or triacylglycerols having 8 to 12 carbons in hydrocarbon chains, 0.01 to 20 (w/w)% of one or more emulsifiers including o cationic biological surface-active agent, and an aqueous solution.
- the present invention also comprises the methods of preparing the emulsions.
- Figure 1 is a graph showing an average droplet size of the lipid emulsion, BRC 001 of the present invention as a function of the potassium chloride concentration;
- Figure 2 is a graph showing an average zeta ( ⁇ ) potential of the lipid emulsion, BRC 001 of the present invention as a function of the potassium chloride concentration;
- Figure 3 is an electrophoresis photograph showing a complex formation between DNA and BRC 001 of the present invention
- FIG. 4 is a thin Layer Chromatography (TLC) autoradiogram showing an effect of a lipid emulsion concentration on a gene transfection efficiency in COS-1 cell line when forming the complex between DNA and BRC 001 of the present invention
- Figure 5 is a TLC autoradiogram showing an effect of a lipid emulsion concentration on a gene transfection efficiency in CV-1 cell line when forming a complex between DNA and BRC 001 of the present invention
- Figure 6 is a TLC autoradiogram showing an effect of a lipid emulsion concentration on a gene transfection efficiency in HeLa cell line when forming a complex between DNA and BRC 001 of the present invention
- Figure 7 is a TLC autoradiogram showing an effect of a lipid emulsion concentration on a gene transfection efficiency in K562 Lymphoma cell line when forming a complex between DNA and BRC 001 of the present invention
- Figure 8 is a TLC autoradiogram showing an effect of an incubation time of DNA-BRC 001 complex on a CAT gene expression
- Figure 9a is a TLC autoradiogram showing a serum effect on a CAT gene expression when Lipofectamine is used as a gene carrier in COS-1 cell line;
- Figure 9b is a TLC autoradiogram showing a serum effect on a CAT gene expression when BRC 001 of the present invention is used as a gene carrier in COS-1 cell line;
- Figure 10a is a TLC autoradiogram showing a serum effect on a CAT gene expression when Lipofectamine is used as a gene carrier in CV-1 cell line
- Figure 10b is a TLC autoradiogram showing a serum effect on a CAT gene expression when BRC 001 of the present invention is used as a gene carrier in CV-1 cell line;
- Figure 11 is a TLC autoradiogram showing a serum effect on a CAT gene expression when pure DOTAP liposome is used as a gene carrier in COS-1 cell line;
- Figure 12 is a TLC autoradiogram showing a result of a gene transfection by using commercially available liposome carriers: Lipofectin, Lipofectamine and Liofectace in COS-1 cell line;
- Figure 13 is an X-gal staining photograph showing COS-1 cells after a gene transfection using Lipofectamine and BRC 001 of the present invention as carriers;
- Figure 14 is an electrophoresis photograph showing that lipid carriers protect DNA against an enzyme digestion by DNAase I;
- Figure 15 is an electrophoresis photograph showing a stability of a carrier-DNA complex when exposed to poly-L aspartic acid
- Figure 16 is a graph showing a comparison of a gene transfection efficiencies between emulsions prepared by different methods
- Figure 17 is a graph showing a comparison of an intranasal gene transfection efficiency between different gene carriers in Balb/C mice
- Figure 18 is a graph showing a comparison of an intramuscular gene transfection efficiency between different gene carriers in Balb/C mice;
- Figure 19 is a TLC autoradiogram showing a gene expression in different organs after a systemic delivery of a DNA-BRC 001 complex via an intravenous injection;
- Figure 20 is a graph showing a cell viability as a function of BRC 001 concentration of the present invention.
- Figure 21 a is a graph showing a size of DNA-BRC 001 complex as a function of DNA/DOTAP ratio
- Figure 21 b is a graph showing a zeta potential of DNA-BRC 001 complex as a function of DNA/DOTAP ratio
- Figure 22a is a graph showing a size of DNA-BRC 001 complex of emulsions of the present invention prepared by different methods.
- Figure 22b is a graph showing a zeta potential of DNA-BRC 001 complex of emulsions of the present invention prepared by different methods. MODES FOR CARRYING OUT THE INVENTION
- the present invention relates to an oil-in-water (o/w) type lipid emulsions that can deliver genes and biologically active materials into cells.
- the emulsions are composed of 2 to 30 (w/w)% of one or more oils selected from vegetable oils and/or triacylglycerols having 8 to 12 carbons in hydrocarbon chains, 0.01 to 20 (w/w)% of one or more emulsifiers, including cationic surface-active materials, and an aqueous solution, in addition, other additives may be optionally added.
- Examples of the vegetable oils that may be used in the compositions of the present invention are soybean, cottonseed, olive and poppyseed oils.
- the cationic surface-active agents, phospholipids or non-ionic surface-active agents can be used as the emulsifiers in the composition of the present invention.
- the cationic surface-active agents that may be used in the compositions of the present invention are 1 ,2-dioleoyl-3- trimethylammonium-propane (DOTAP), dimethyldioctadecylammonium chloride (DDAB) and N-[1 -(1 ,2-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA).
- DOTAP 1,2-dioleoyl-3- trimethylammonium-propane
- DDAB dimethyldioctadecylammonium chloride
- DOTMA N-[1 -(1 ,2-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride
- phospholipids examples include phosphatidylcholine, phosphatidylethanolamine and phosphatidylserine, and their respective derivatives.
- DOPE 1,2-dioleoyl-sn-3- phosphatidylethanolamine
- non-ionic surface-active agents examples include poloxamers (also known as pluronic: a copolymer of polyoxyethylene and polyoxypropylene), sorbitan esters (Span) and polyoxyethylene-sorbitan fat acid esters (Tween).
- poloxamers also known as pluronic: a copolymer of polyoxyethylene and polyoxypropylene
- Span sorbitan esters
- Teween polyoxyethylene-sorbitan fat acid esters
- the present invention may comprise of hydrophilic polymers or polymeric lipid where the hydrophilic polymers are covalently-bonded to a phospholipid.
- hydrophilic polymers examples include polyoxyethylene, polyethyloxazoline and polyethyleneglycol (PEG).
- PEG polyethyleneglycol
- PEG and polymeric lipid enhance the sterical stability of the emulsion, and also PEG with a small molecular weight is a well-known fusogenic agent.
- compositions of the present invention may also comprise of an osmotic pressure regulator such as glycerol.
- the present invention may also comprise of low-molecular weight polyethylene glycol (average molecular weight in the range of 500-1000) and fusogenic peptide, such as HA gp 41 , to improve the transfection efficiency.
- low-molecular weight polyethylene glycol average molecular weight in the range of 500-1000
- fusogenic peptide such as HA gp 41
- the present invention may also comprise of materials such as glycolipid, lipopeptide, antibody, ligand for receptors, viral protein to target specific cells or organs.
- lipid emulsion of the present invention is physically stable and has high transfection efficiency in the presence of serum (Fig. 6).
- the present invention relates to the method of preparing the oil-in-water
- the emulsions of the present invention is prepared by the oily solution containing 2 to 30 (w/w)% of one or more oils selected from vegetable oils and/or triacylglycerols having 8 to 12 carbons in the
- hydrocarbon chains 15 hydrocarbon chains, 0.01 to 20 (w/w)% of one or more emulsifiers including cationic surface-active agents, and the aqueous solution, in addition, other additives may be optionally added.
- the two solutions are prepared separately.
- the oily and aqueous solutions are mixed by using a well known procedure in this field.
- the emulsification can be achieved by using such tools, as a stirrer, vortex mixer, homogenizer, sonicator, microfluidizer, etc.
- the present invention may also comprise the method of delivering biologically active material such as DNA into the cells by using lipid emulsions.
- the method of delivering the materials is to prepare the complex of the emulsion of the present invention and the biologically active material, and to transfer the complex into the target cells.
- the biologically active material is selected from a group comprising of DNA, ribonucleic acid(RNA), antisense nucleic acid, ribosome, polynucleotide, oligonucleotide and other pharmaceutical drugs.
- the cell is selected from a group comprising of white blood cells, fibroblasts, cancer cells, cells infected with virus, epithelial cells, endothelial cells, muscle cells, liver cells, endocrine cells, neural cells, dermal cells, germ cells, oocytes, sperms, hematopoietic cells, fetal cells, M cells, Langerhans islet cells, microphages, plant cells, animal cells, and immotalized cell lines.
- the lipid emulsion of the present invention when used as the carrier of genetic materials, it can be administered intravenously, intramuscularly, intranasally, intratracheally, subcutaneously, parenterally, by a topical administration, or direct administration to a specific organ. It can be used as a vaccine, in a diagnostic kit and for therapy.
- Example 1 Preparation of the emulsion (BRC 001 )
- the emulsion which has components and compositions in this example is labled BRC 001 to distinguish it from the emulsions in other examples.
- the lipid emulsion, BRC 001 was prepared by using the following procedure.
- Example 1 -1 Preparation of BRC 001 by using a homogenizer and Microfluidizer
- the oily solution consisted of the following ingredients (expressed in weight %):
- soybean oil (Sigma Chemical Company, St. Louis, MO); - 0.4 % 1 ,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE, Avanti Polar Lipids, Alabaster, AL);
- DOTAP 0.8 % 1 ,2-dioleoyl-sn-glycero-3-trimethylammonium-propane
- the two solutions were heated at 70°C and stirred separately to completely solubilize the components.
- the emulsion was prepared by mixing the two solutions with a high-speed homogenizer (T-25-Ultra-Turrax, S25-18G, IKA Werke, Janke & Kunkel GmbH & Co KG, Germany) at 8000 rpm for 10 min. The mixture was passed 10 times through a Microfluidizer® (Microfluidics Co., Newton, MA) with an exit air pressure of 80 psi. The emulsion was kept at 4 ° C until further use.
- the emulsion was diluted 300 times with DDW (> 18 M ⁇ ) to measure its droplet size and zeta potential.
- the zeta potential is the potential of the droplets in the emulsion at the surface of shear.
- Example 1 -2 Preparation of BRC 001 by using a sonicator.
- the oily and aqueous solutions were prepared as in example 1 -1.
- the two solutions were heated at 70°C separately to completely solubilize the components.
- the emulsion was prepared by sonicating the mixture by using a probe-type sonicator (High intensity ultrasonic processor, 600 W model) for 2 min.
- the emulsion was diluted 300 times with DDW to measure its size and surface potential.
- the emulsion was kept at 4°C until further use.
- Example 1 -3 Preparation of BRC 001 by using a sonicator.
- the oily solution of example 1 -1 was prepared, except for the use of the soybean oil and was completely dissloved with the addition of chloroform.
- the chloroform was subsequently removed by using a rotary evaporator (Buchi Rotavapor, Switzerland) to form a lipid film around an inside wall of a round-bottomed flask.
- An identical aqueous solution as in example 1 -1 was added to the lipid film.
- the solution was sonicated to form a liposome solution. Soybean oil was added to this liposome solution and further sonicated for 2 minutes to formulate the emulsion.
- the emulsion was diluted 300 times with DDW (> 18 M ⁇ ) to measure its size and surface potential.
- the emulsion was kept at 4 ° C until further use.
- Example 2-2 Variation of the core oils in the emulsion
- the lipid emulsions were prepared by using the method as in example
- Tricaprylin is a triacylglycerol that has 8 carbons in the hydrocarbon chain.
- Example 2-3 Variation of other components in the emulsion
- the lipid emulsions were prepared by changing other constituents by using the method as in example 1 -2.
- Pluronic F68 BASF Corp., Parsippany NJ
- GM1 ganglioside Sigma
- the average droplet size and the zeta potential of the emulsion were measured by using the same method as in example 1 -1 (Table 3).
- Example 3-1 Stability of emulsions in PBS solution
- Example 3-2 Stability of emulsions in PBS solution
- the BRC 001 prepared as in example 1 -1 was sterilized by autoclaving at 120° C for 20 min.
- the sterilized emulsions were diluted 300 times in DDW for the size and zeta potential measurements (Table 5).
- Table 5 Table 5
- Example 3-3 Stability of emulsions in KCl solutions
- Stability of the BRC 001 as prepared in example 1 -1 was tested in various concentrations of potassium chloride (KCl) solutions.
- the size and the zeta potential of the BRC 001 were measured after diluting the emulsion 300 times in KCl solutions of different concentrations. The results are shown in Figures 1a and 1 b, respectively.
- the size of the emulsion did not change for 24 h after the dilution.
- the emulsion was stable in the KCl solutions of high concentrations. This result shows that the steric repulsion could provide the emulsion stability.
- the steric repulsion that polyethylene glycol moiety of the PEG 2000 PE provides is one of the most important emulsion stabilizing factor.
- COS-1 cells (kidney, SV40 transformed, African green monkey) were grown in RPMI1640 supplemented with 10 % fetal bovine serum (FBS), 100 units/ml penicillin, and 100 g/ml streptomycin.
- HeLa cells Human cervical carcinoma
- DMEM fetal bovine serum
- 10 mM non-essential amino acids 100 units/ml penicillin, and 100 ⁇ g/ml streptomycin.
- plasmid DNA containing the chloramphenicol acetyl transferase driven by a SV40 (pSV-CAT) or a CMV (pCMV-CAT) promoters or a plasmid where a CMV promoter drove the expression of ⁇ -galactosidase with a nuclear localization signal (pCMV-gal) as reporter genes was purchased from Promega, Wl, U.S.A.
- the plasmid was amplified in the Escherichia coli (E.Coli) HB101 strain and purified by an alkaline lysis technique according to Quiagen (Quiagen Inc., Chatsworth, CA) mega-kit preparation protocol as described in the manufacturer's instruction.
- the complex formation between pSV-CAT gene and BRC was observed by using a gel electrophoresis technique.
- the pSV-CAT gene was diluted to a concentration of 5 ⁇ g per 100 ⁇ l in serum free RPMI.
- Various concentrations of lipid emulsion solutions diluted in 100 ⁇ l of RPMI 1640 medium were added to the DNA solutions and incubated for 20 to 60 minutes at room temperature.
- Lipofectamine® also diluted in the same medium ( 20 ⁇ g / 100 ⁇ l) was added to the DNA solution.
- the DNA-liposome complexes were formed after a 20 minute incubation at room temperatures according to the manufacturer's protocol.
- the size and zetapotential changes are shown in Tables 6 and Table 7, respectively.
- the BRC 001 's size nor zeta potential change before or after the complex formation with DNA This suggest that the mechanism for the BRC 001 -DNA complex formation is different from that for Lipofectamine-DNA.
- COS-1 cells were seeded at 5 x 10 5 cells in a 60 mm-diameter dish one day prior to the transfection.
- Five (5) ⁇ g of pSV-CAT plasmid DNA were mixed with 0.02, 0.033, 0.1 , 1 , 3, 6, 9, 12, 15 and 20 ⁇ l each of the BRC 001 , respectively.
- the mixtures were diluted in 100 ⁇ l of serum free RPMI 1640 medium.
- Ten (10) ⁇ l of Lipofectamine was used instead of the BRC 001 as a control. The mixtures were completely shaken three times during an one-hour incubation period. After cleaning the COS-1 cells with serum free RPMI 1640, 800 ⁇ l serum free media and carrier-DNA mixture were added to them.
- the protein concentration in supernatant was measured with a micro BCA protein assay reagent kit (Pierce, USA), and equal amounts of homogenate were assayed as described by the manufacturer.
- the results indicate that the BRC 001 of the present invention can transfer DNA into COS-1 cells in a concentration-dependent fashion.
- Example 8-1 Effect of serum on transfection efficiency in COS-1 cell line
- carrier-DNA complexes were prepared in RPMI 1640 without serum. These complexes were applied to the cells in RPMI medium containing various concentrations of FBS (up to 90 %) for 4 hours and the medium was changed with fresh RPMI with 10 % FBS. The transfected cells were harvested in 48 hours and analyzed as in example 6-1 (Fig. 9). In the presence of serum, the transfection efficiency decreased sharply for the Lipofectamine-DNA complex (Fig. 9A). For the BRC 001 -DNA complex, however, the transfection efficiency did not decrease with up to 90 % serum (Fig. 9B). The result indicates that BRC 001 can be used as a stable gene carrier for in vivo applications.
- Example 8-2 Effect of serum on transfection efficiency in CV-1 cell line
- Example 8-3 Effect of serum on transfection efficiency of pure DOTAP liposome in COS-1 cell line
- the BRC 001 -DNA complex in serum free media (BRC 001 -SFM), and in the media containing 50 % serum (BRC 001 - 50 %serum) and the BRC 002 liposome-DNA complex in serum free media (BRC 002) were used as controls.
- the pure DOTAP liposome did not show transfection efficiency in the presence of higher than 20 % serum concentration.
- the BRC 001 of the present invention can transfer DNA into HepG2 cells in a concentration-dependent fashion.
- the BRC 001 -DNA (pSV-CAT) and Lipofectamine-DNA complex were incubated for 1 h at room temperature. Zero point five (0.5) or 1.0 unit each of DNAase I were added to the complex and incubated for 30 min at 37° C. Two (2) ⁇ l of the Lipofectamine or BRC 001 and 1 ⁇ g of DNA were used for the experiment (Fig 14). Lanes 1 and 2 show the DNA size marker and DNA in the absence of DNAase, respectively.
- DNA-Lipofectamine complex with 0.5 (Lane 4) and 1.0 (Lane 5) unit of DNAase I and DNA-BRC 001 complex with 0.5 (Lane 7) and 1.0 (Lane 8) unit of DNAase I are also shown.
- a naked DNA was digested by DNAase I. However, DNA that formed complex with the carriers were protected by the Lipofectamine and by BRC 001.
- the DNA complexes were formed with the Lipofectamine and BRC 001 as in example 11. Different concentrations of poly-L-aspartic acid (PLAA) were added to the complex. Since PLAA is an anionic polymer, it could dissociate the anionic DNA from the complex. Therefore, the dissociation of DNA from the complex in the presence of PLAA is an indicator for the strength of the complex. DNA was dissociated from the Lipofectamine-DNA complex at a low PLAA concentration. On the other hand, the BRC 001 -DNA complex remained stable in the PLAA concentration range studied.
- PLAA poly-L-aspartic acid
- Example 13 Comparison of transfection efficiencies with and without serum by using different preparation methods
- the BRC 001 were prepared by using the procedures as in examples 1 -1 and 1 -3.
- the transfection efficiencies of the BRC 001 - DNA were compared in the presence and in the absence of serum (Fig. 16). All other procedures were identical as in example 11.
- the Lipofectamine was used as a control.
- the transfection efficiency decreased greatly in the presence of serum in case of the Lipofectamine.
- the BRC 001 showed almost identical efficiency with or without serum.
- the BRC 001 by sonication (so, as in example 1-3) showed higher transfection efficiency than that by microfluidization (mf, as in example 1 -1 ) by a factor of ca. 1.5 to 1.8 whether serum was the presentor not.
- the complex was prepared with 100 ⁇ l of BRC 001 and 50 ⁇ g of pCMV-CAT plasmid DNA having the same conditions as example 1 1.
- the final volume of the solution was adjusted to 160 ⁇ l with PBS.
- the 40 ⁇ l of solutions were delivered via intranasal route to the Balb/c mice for four times.
- the mice were sacrificed 48 hours after the final administration.
- a CAT assay was performed from the nasal extracts ( Figure 17).
- the mice that received naked DNA or the complex with liposomes Lipofectamine; L/P or Lipofectin; L/F
- the mice that received the BRC-DNA complex showed high transfection efficiency (1.0).
- the complex was prepared as in example 14 having the same conditions as example 11.
- the 40 ⁇ l of solutions were delivered via intramuscular injection in the thigh region of the Balb/c mice four times.
- the mice were sacrificed at 48 hours after the final administration.
- the CAT assay was performed from the muscle extracts at the site of injection ( Figure 18).
- the transfection efficiency for the mice that received the BRC 001 was almost twice than others used in the experiment.
- Example 16 Systemic delivery via intravenous injection (In vivo experiment)
- Live cells can be quantified by using a 3-(4,5-dimethylthiazol-2-yl)-
- TMTT 2,5-diphenyl- tetrazolium bromide
- the BRC 001 of the present invention was prepared by the microfluidization (as in example 1 -1 ) and by the sonication (1-3).
- the COS1 cells were harvested from exponential phase culture by trypsinization, counted and plated in 96-well microplates. A concentration of 5000 cells/well was found suitable. Plates were incubated at 37° C for 1 day under a humidified atmosphere.
- the BRC 001 was added to the cells in different concentrations and incubated for 24 hours. After exposure with a lipid emulsion, the cells were washed twice with PBS. MTT was dissolved in PBS, filter-sterilized and stored at 4° C until further experiment.
- Solution A the BRC 001 was diluted with RPMI 1640 media to prepare a final volume of 100 ⁇ l.
- Solution B 2.5 ⁇ g of DNA (pSV-CAT or pCMV CAT) was diluted in 100 ⁇ l
- RPMI 1640 media Solutions A and B were mixed and incubated at room temperature for 30 mins. After the incubation, RPMI 1640 media was added to a total volume of 2 ml to measure the emulsion droplet size (Fig. 21 a).
- the sample preparation method is identical to the size measurement except that DDW was used in instead of the RPMI 1640 to the dilute BRC 001 and DNA (Fig. 21 b).
- DDW was used in instead of the RPMI 1640 to the dilute BRC 001 and DNA (Fig. 21 b).
- Conventional liposome and polymer gene carriers formed aggregate with DNA resulting bigger droplets of emulsions. The transfection efficiency decreases dramatically as these aggregates are formed.
- the size and distribution of the lipid emulsion of the present invention did not change in the presence of high DNA concentration. Therefore, the emulsion of the present inventioncould be used as gene carriers at high DNA concentrations.
- the BRC 001 emulsions were prepared by sonication (as in example
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU58824/98A AU5882498A (en) | 1997-01-31 | 1998-01-31 | Lipid emulsions as gene transfection agents and method of preparing said emul sions |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1997/3022 | 1997-01-31 | ||
KR1019970003022A KR19980067138A (en) | 1997-01-31 | 1997-01-31 | Fat emulsions for efficiently delivering genes or biologically active drugs into cells and methods for preparing the same |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998033932A1 true WO1998033932A1 (en) | 1998-08-06 |
Family
ID=19496119
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR1998/000020 WO1998033932A1 (en) | 1997-01-31 | 1998-01-31 | Lipid emulsions as gene transfection agents and method of preparing said emulsions |
Country Status (3)
Country | Link |
---|---|
KR (1) | KR19980067138A (en) |
AU (1) | AU5882498A (en) |
WO (1) | WO1998033932A1 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1080103A1 (en) * | 1998-05-21 | 2001-03-07 | Isis Pharmaceuticals, Inc. | Compositions and methods for non-parenteral delivery of oligonucleotides |
WO2001030385A1 (en) * | 1999-10-26 | 2001-05-03 | Id-Lelystad, Instituut Voor Dierhouderij En Diergezondheid B.V. | Adjuvants for nucleic acid vaccines |
FR2806913A1 (en) * | 2000-03-31 | 2001-10-05 | Pf Medicament | USE OF ALIPHATIC QUATERNARY AMMONIUMS AS ADJUVANT IN A MUCOSAL ADMINISTRATIVE PHARMACEUTICAL COMPOSITION |
JP2002537102A (en) * | 1999-02-26 | 2002-11-05 | カイロン コーポレイション | Microemulsion with adsorbed polymer and fine particles |
US6887906B1 (en) | 1997-07-01 | 2005-05-03 | Isispharmaceuticals, Inc. | Compositions and methods for the delivery of oligonucleotides via the alimentary canal |
US8900627B2 (en) | 2008-06-06 | 2014-12-02 | Mirna Therapeutics, Inc. | Compositions for the in vivo delivery of RNAi agents |
US9445975B2 (en) | 2008-10-03 | 2016-09-20 | Access Business Group International, Llc | Composition and method for preparing stable unilamellar liposomal suspension |
US10287544B2 (en) * | 2013-05-31 | 2019-05-14 | Newleaf Symbiotics, Inc. | Bacterial fermentation methods and compositions |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DD238720A1 (en) * | 1985-06-27 | 1986-09-03 | Adw Ddr | PROCESS FOR PRODUCING FOOD EMULSIONS |
US5332595A (en) * | 1991-03-18 | 1994-07-26 | Kraft General Foods, Inc. | Stable multiple emulsions comprising interfacial gelatinous layer, flavor-encapsulating multiple emulsions and low/no-fat food products comprising the same |
WO1995017953A1 (en) * | 1993-12-30 | 1995-07-06 | Fmc Corporation | High internal phase water/oil emulsions and water/oil/water emulsions |
WO1996008235A1 (en) * | 1994-09-13 | 1996-03-21 | Depotech Corporation | Preparation of multivesicular liposomes for controlled release of active agents |
-
1997
- 1997-01-31 KR KR1019970003022A patent/KR19980067138A/en active Search and Examination
-
1998
- 1998-01-31 WO PCT/KR1998/000020 patent/WO1998033932A1/en active Application Filing
- 1998-01-31 AU AU58824/98A patent/AU5882498A/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DD238720A1 (en) * | 1985-06-27 | 1986-09-03 | Adw Ddr | PROCESS FOR PRODUCING FOOD EMULSIONS |
US5332595A (en) * | 1991-03-18 | 1994-07-26 | Kraft General Foods, Inc. | Stable multiple emulsions comprising interfacial gelatinous layer, flavor-encapsulating multiple emulsions and low/no-fat food products comprising the same |
WO1995017953A1 (en) * | 1993-12-30 | 1995-07-06 | Fmc Corporation | High internal phase water/oil emulsions and water/oil/water emulsions |
WO1996008235A1 (en) * | 1994-09-13 | 1996-03-21 | Depotech Corporation | Preparation of multivesicular liposomes for controlled release of active agents |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8691785B2 (en) | 1997-07-01 | 2014-04-08 | Isis Pharmaceuticals, Inc. | Compositions and methods for non-parenteral delivery of oligonucleotides |
US6887906B1 (en) | 1997-07-01 | 2005-05-03 | Isispharmaceuticals, Inc. | Compositions and methods for the delivery of oligonucleotides via the alimentary canal |
EP1080103A4 (en) * | 1998-05-21 | 2003-07-02 | Isis Pharmaceuticals Inc | Compositions and methods for non-parenteral delivery of oligonucleotides |
EP1080103A1 (en) * | 1998-05-21 | 2001-03-07 | Isis Pharmaceuticals, Inc. | Compositions and methods for non-parenteral delivery of oligonucleotides |
US8206749B1 (en) | 1999-02-26 | 2012-06-26 | Novartis Vaccines And Diagnostics, Inc. | Microemulsions with adsorbed macromolecules and microparticles |
JP2002537102A (en) * | 1999-02-26 | 2002-11-05 | カイロン コーポレイション | Microemulsion with adsorbed polymer and fine particles |
EP2286792A1 (en) * | 1999-02-26 | 2011-02-23 | Novartis Vaccines and Diagnostics, Inc. | Microemulsions with an adsorbent surface, comprising a microdroplet emulsion |
JP2012017344A (en) * | 1999-02-26 | 2012-01-26 | Novartis Vaccines & Diagnostics Inc | Microemulsion with adsorbed macromolecule and microparticle |
US8309139B2 (en) | 1999-02-26 | 2012-11-13 | Novartis Vaccines And Diagnostics, Inc. | Microemulsions with adsorbed macromolecules and microparticles |
US8734832B2 (en) | 1999-02-26 | 2014-05-27 | Novartis Ag | Microemulsions with adsorbed macromolecules and microparticles |
US8771747B2 (en) | 1999-02-26 | 2014-07-08 | Novartis Vaccines And Diagnostics, Inc. | Microemulsions with adsorbed macromolecules and microparticles |
JP2014169323A (en) * | 1999-02-26 | 2014-09-18 | Novartis Vaccines & Diagnostics Inc | Microemulsions with adsorbed macromolecules and microparticles |
WO2001030385A1 (en) * | 1999-10-26 | 2001-05-03 | Id-Lelystad, Instituut Voor Dierhouderij En Diergezondheid B.V. | Adjuvants for nucleic acid vaccines |
FR2806913A1 (en) * | 2000-03-31 | 2001-10-05 | Pf Medicament | USE OF ALIPHATIC QUATERNARY AMMONIUMS AS ADJUVANT IN A MUCOSAL ADMINISTRATIVE PHARMACEUTICAL COMPOSITION |
US8900627B2 (en) | 2008-06-06 | 2014-12-02 | Mirna Therapeutics, Inc. | Compositions for the in vivo delivery of RNAi agents |
US9445975B2 (en) | 2008-10-03 | 2016-09-20 | Access Business Group International, Llc | Composition and method for preparing stable unilamellar liposomal suspension |
US10287544B2 (en) * | 2013-05-31 | 2019-05-14 | Newleaf Symbiotics, Inc. | Bacterial fermentation methods and compositions |
Also Published As
Publication number | Publication date |
---|---|
KR19980067138A (en) | 1998-10-15 |
AU5882498A (en) | 1998-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000006120A1 (en) | Lipid emulsion and solid lipid nanoparticle as a gene or drug carrier | |
US10155945B2 (en) | Method of producing lipid nanoparticles for drug delivery | |
Maurer et al. | Lipid-based systems for the intracellular delivery of genetic drugs | |
EP0852490B1 (en) | Emulsion formulations for the delivery of nucleic acids to cells | |
US6303378B1 (en) | Methods for preparing polynucleotide transfection complexes | |
Yi et al. | A cationic lipid emulsion/DNA complex as a physically stable and serum-resistant gene delivery system | |
Liu et al. | Factors controlling the efficiency of cationic lipid-mediated transfection in vivo via intravenous administration | |
US5908777A (en) | Lipidic vector for nucleic acid delivery | |
US5908635A (en) | Method for the liposomal delivery of nucleic acids | |
US6235310B1 (en) | Methods of delivery using cationic lipids and helper lipids | |
US7491409B1 (en) | Encapsulation of bioactive complexes in liposomes | |
Kim et al. | The effects of serum on the stability and the transfection activity of the cationic lipid emulsion with various oils | |
JP2002520038A (en) | Liposome encapsulated nucleic acid complex | |
Sato et al. | Neutralization of negative charges of siRNA results in improved safety and efficient gene silencing activity of lipid nanoparticles loaded with high levels of siRNA | |
Kim et al. | In vivo gene transfer to the mouse nasal cavity mucosa using a stable cationic lipid emulsion | |
PL199201B1 (en) | Cationic virosomes as a genetic material carrying system | |
US20030162293A1 (en) | Cell transfection compositions comprising genetic material, an amphipathic compound and an enzyme inhibitor and method of use | |
WO1998033932A1 (en) | Lipid emulsions as gene transfection agents and method of preparing said emulsions | |
EP1955695A1 (en) | Nanocapsules of lipophilic complexes of nucleic acids | |
Bally et al. | Lipid/DNA complexes as an intermediate in the preparation of particles for gene transfer: an alternative to cationic liposome/DNA aggregates | |
Couvreu et al. | pH-sensitive liposomes: an intelligent system for the delivery of antisense oligonucleotides | |
CA2269502C (en) | Tetraether lipid derivatives and liposomes and lipid agglomerates containing tetraetherlipid derivatives, and use thereof | |
WO2001042424A2 (en) | Sphingolipid-containing cationic liposomes for topical delivery of bioactive material | |
KR100428418B1 (en) | Iodized oil emulsion as an efficient physiologically active materials or drug carrier and preparation method thereof | |
Asokan et al. | Cytosolic delivery of macromolecules: 4. Head group-dependent membrane permeabilization by pH-sensitive detergents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 1998532739 Format of ref document f/p: F |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
122 | Ep: pct application non-entry in european phase |